Malawian children with chest-indrawing pneumonia with and without comorbidities or danger signs

Amy Sarah Ginsburg1, Tisungane Mvalo2, Melda Phiri2

  • 1University of Washington, Seattle, Washington, USA.

Insights

Children with chest-indrawing pneumonia and comorbidities like HIV, malaria, or malnutrition had worse cure rates at Day 14. Intensive follow-up may benefit these vulnerable pediatric patients, even without danger signs.

Area of Science:

  • Pediatric infectious diseases
  • Clinical trial research
  • Global health

Background:

  • Children with comorbidities are often excluded from pneumonia treatment trials.
  • This exclusion limits understanding of treatment efficacy in vulnerable populations.

Purpose of the Study:

  • To compare cure rates in children with chest-indrawing pneumonia and comorbidities versus those without.
  • To assess the impact of HIV, malaria, malnutrition, and anemia on pneumonia treatment outcomes.

Main Methods:

  • Prospective observational cohort study of children with comorbidities.
  • Concurrent prospective randomized controlled trial for comparison.
  • Evaluated cure rates at Day 14 in Lilongwe, Malawi.

Main Results:

  • Children with comorbidities (HIV, malaria, malnutrition) had higher rates of not being cured at Day 14.
  • No significant difference in Day 6 treatment failure rates for comorbidities without danger signs.
  • Significant cure failure rates at Day 14 for HIV-exposed/infected and malnourished children without danger signs.

Conclusions:

  • Children with chest-indrawing pneumonia and comorbidities require careful monitoring.
  • Intensive follow-up may improve outcomes for these children, even without initial danger signs.
Abstract

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
566
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
467
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.5K
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
726
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.9K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
555